Page d'accueilPlan du siteAjouter aux FavorisImprimerEnvoyer à un ami
 new critical players in cancer
Welcome to the Jauliac lab home page

Sébastien Jauliac is a principal investigator in the Department of Cancer at INSERM in the HIPI U976 laboratory at the IRSL, Hospital saint-Louis, University Paris Diderot, in Paris.

Our team works on the molecular mechanisms involved in breast cancer metastases formation. We study the role of NFAT transcription factors in the regulation of the migratory and invasive capacities of breast carcinoma, contributing to the formation of metastases. We currently work on both the identification of the mechanisms of NFAT transcription factors activation and the identification of their downstream genes required to increase or blunt the cellular motility. The goals of these studies is to be able to provide new therapeutic targets to prevent or cure breast cancer metastases.

Our discovery of the expression and function of the NFAT transcription factors in breast cancer (Jauliac et al. 2002; Yeoli-Lerner et al., 2005; Fougère et al. 2010) has allowed for the first time to highlight the key role of these transcription factors in breast cancer biology and other cancers types (Bégué et al., 2012). Our team have identified key genes targeted by the NFAT transcription factors to modulate breast cancer carcinoma motility (Fougère et al., 2010; Germann et al., 2012; Gaudineau et al., 2012). Critically we have shown that depending on the NFAT isotype and the cellular context the consequences on genes regulation and cell motility can be completely divergent (Fougère et al., 2010; Gaudineau et al., 2012).
We recently showed that NFAT3-expressing cells are competent in producing extracellular vesicles with a capacity to impair tumor growth and metastases development in vivo (de Camargo, L.C.B. et al., 2020).
Our studies open new fields of research in the study  and treatment of aggressive cancers 

Recent Lab News 

*** Grant awarded from the Gefluc association***

Our team has identified vesicles produced by poorly metastatic cells capable of blocking tumor growth and the appearance of metastases in a model of breast cancer. Besides breast cancer, these vesicles also have an anti-tumor power on pancreatic cancer, melanoma and glioblastoma.The project funded by Gefluc aims to identify which factors, present within these vesicles, are decisive in limiting tumor progression and the appearance of metastases with a view to developing new effective therapies to treat aggressive cancers.

link to the video


*** Paper Published ***

Extracellular vesicles produced by NFAT3-expressing cells hinder tumor growth and metastatic dissemination.

Lívia Cardoso Bueno de Camargo, Frédéric Guaddachi, David Bergerat, Nadia Ourari, Lucie Coillard, Veronique Parietti, Morgane Le Bras, Jacqueline Lehmann-Che & Sébastien Jauliac

Scientific Reports, 10, 8964 (2020).

*** Highlighted in INSERM magazine ***

Lab Supports

Lab directions
Agrandir la carte
Créer un site avec WebSelf